Bhatti, Jasvinder SinghKhullar, NainaMishra, JayapriyaKaur, SatinderSehrawat, AbhishekSharma, EvaBhatti, Gurjit KaurSelman, AshleyReddy, P. Hemachandra2024-01-212024-08-142024-01-212024-08-142023-04-06925443910.1016/j.bbadis.2023.166712http://10.2.3.109/handle/32116/4248Alzheimer's disease (AD) is the most widespread form of neurodegenerative disorder that causes memory loss and multiple cognitive issues. The underlying mechanisms of AD include the build-up of amyloid-? and phosphorylated tau, synaptic damage, elevated levels of microglia and astrocytes, abnormal microRNAs, mitochondrial dysfunction, hormonal imbalance, and age-related neuronal loss. However, the etiology of AD is complex and involves a multitude of environmental and genetic factors. Currently, available AD medications only alleviate symptoms and do not provide a permanent cure. Therefore, there is a need for therapies that can prevent or reverse cognitive decline, brain tissue loss, and neural instability. Stem cell therapy is a promising treatment for AD because stem cells possess the unique ability to differentiate into any type of cell and maintain their self-renewal. This article provides an overview of the pathophysiology of AD and existing pharmacological treatments. This review article focuses on the role of various types of stem cells in neuroregeneration, the potential challenges, and the future of stem cell-based therapies for AD, including nano delivery and gaps in stem cell technology. � 2023 Elsevier B.V.en-USAlzheimer's diseaseAmyloid-? plaquesBlood-brain barrierNanoparticlesNeurofibrillary tanglesStem cell therapyReviewhttps://linkinghub.elsevier.com/retrieve/pii/S0925443923000789